Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Utility of Lymphadenectomy in Prostate Cancer: Where do We Stand?

Version 1 : Received: 13 March 2022 / Approved: 16 March 2022 / Online: 16 March 2022 (02:24:15 CET)

A peer-reviewed article of this Preprint also exists.

Małkiewicz, B.; Kiełb, P.; Karwacki, J.; Czerwińska, R.; Długosz, P.; Lemiński, A.; Nowak, Ł.; Krajewski, W.; Szydełko, T. Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand? J. Clin. Med. 2022, 11, 2343. Małkiewicz, B.; Kiełb, P.; Karwacki, J.; Czerwińska, R.; Długosz, P.; Lemiński, A.; Nowak, Ł.; Krajewski, W.; Szydełko, T. Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand? J. Clin. Med. 2022, 11, 2343.

Journal reference: J. Clin. Med. 2022, 11, 2343
DOI: 10.3390/jcm11092343

Abstract

The purpose of this review is to summarize current knowledge on lymph node dissection (LND) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP). Despite a growing body of evidence, utility, therapeutic and prognostic value of such approach as well as optimal extent of LND, remain unsolved issues. Although LND is the most accurate staging procedure, the direct therapeutic effect is still not evident from the current literature which limits the possibility of establishing clear recommendations. This indicates the need for further robust and adequately designed high quality clinical trials.

Keywords

prostate cancer; lymph node dissection; lymphadenectomy; radical prostatectomy

Subject

MEDICINE & PHARMACOLOGY, Urology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.